Tags: Coronavirus | Coronavirus Special | Health Topics | Vaccines | Cold/Flu | fluvoxamine | luvox

Could a Common Antidepressant Help Fight COVID-19?

a ball and stick molecular model of luvox
A ball and stick molecular model of Luvox (Dreamstime)

By    |   Wednesday, 03 February 2021 04:41 PM

Scientists are researching the potential role a common antidepressant called fluvoxamine could play in preventing severe illness and lung damage in COVID-19 patients. The drug is classified as selective serotonin reuptake inhibitor, or SSRI, and activates a central nervous system protein that regulates inflammation.

According to the Los Angeles Times, Dr. Eric Lenze, a geriatric psychiatrist and associate professor of psychiatry at Washington University School of Medicine, conducted small, clinical trials and found none of the COVID-19 patients treated with fluvoxamine deteriorated, while those patients who were given a placebo did. He published his study results in JAMA.

Further anecdotal studies confirmed the drug's efficacy, but experts say a large, randomized trial is needed to ensure repurposing a psychiatric drug to treat COVID-19 is safe.

The research for fluvoxamine, sold under the brand name Luvox, was funded by the COVID-19 Early Treatment Fund (CETF), according to BioSpace.

"The results of the fluvoxamine trial are encouraging and warrant a further evaluation in a larger study," said Dr. Carolyn Machamer, a professor of cell biology at the Johns Hopkins School of Medicine and a member of CETF's advisory board. "A treatment that can prevent lung problems in people with mild symptoms of COVID-19 is desperately needed."

Researchers in France have conducted large-scale studies and confirmed SSRI drugs significantly decreased the risk of COVID-19 patients needing a ventilator or dying from COVID-19, according to BioSpace.

© 2021 NewsmaxHealth. All rights reserved.


   
1Like our page
2Share
Headline
Scientists are researching the potential role a common antidepressant called fluvoxamine could play in preventing severe illness and lung damage in COVID-19 patients.
fluvoxamine, luvox, antidepressant, drug, pandemic, covid-19, scientists, research, study, treatment
235
2021-41-03
Wednesday, 03 February 2021 04:41 PM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved